MX2020009072A - Composiciones y metodos para inhibir la expresion de gys2. - Google Patents
Composiciones y metodos para inhibir la expresion de gys2.Info
- Publication number
- MX2020009072A MX2020009072A MX2020009072A MX2020009072A MX2020009072A MX 2020009072 A MX2020009072 A MX 2020009072A MX 2020009072 A MX2020009072 A MX 2020009072A MX 2020009072 A MX2020009072 A MX 2020009072A MX 2020009072 A MX2020009072 A MX 2020009072A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- gys2 expression
- gys2
- expression
- inhibiting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01001—Phosphorylase (2.4.1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3519—Fusion with another nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/531—Stem-loop; Hairpin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/01—Hexosyltransferases (2.4.1)
- C12Y204/01011—Glycogen(starch) synthase (2.4.1.11)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862637574P | 2018-03-02 | 2018-03-02 | |
| PCT/US2019/018189 WO2019168687A1 (en) | 2018-03-02 | 2019-02-15 | Compositions and methods for inhibiting gys2 expression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020009072A true MX2020009072A (es) | 2020-10-08 |
Family
ID=67805080
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020009072A MX2020009072A (es) | 2018-03-02 | 2019-02-15 | Composiciones y metodos para inhibir la expresion de gys2. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11572562B2 (enExample) |
| EP (1) | EP3740247A4 (enExample) |
| JP (1) | JP7453921B2 (enExample) |
| KR (1) | KR102804353B1 (enExample) |
| CN (1) | CN112055598B (enExample) |
| AU (1) | AU2019227510B2 (enExample) |
| CA (1) | CA3092092A1 (enExample) |
| IL (2) | IL325191A (enExample) |
| MX (1) | MX2020009072A (enExample) |
| WO (1) | WO2019168687A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020009072A (es) | 2018-03-02 | 2020-10-08 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion de gys2. |
| WO2020226960A1 (en) | 2019-05-03 | 2020-11-12 | Dicerna Pharmaceuticals, Inc. | Double-stranded nucleic acid inhibitor molecules with shortened sense strands |
| IL307154A (en) * | 2021-04-19 | 2023-11-01 | Novo Nordisk As | Compositions and methods for inhibiting nuclear receptor subfamily 1 group h member 3 (nr1h3) expression |
| JP2026520116A (ja) * | 2023-05-11 | 2026-06-22 | 大睿生物 | ＭＡＳＰ２遺伝子活性を制御するためのｄｓＲＮＡ分子 |
| WO2026162643A1 (en) * | 2025-01-31 | 2026-08-06 | Novo Nordisk A/S | Nucleic acid constructs for inhibiting gys2 expression |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030004122A1 (en) * | 1997-11-05 | 2003-01-02 | Leonid Beigelman | Nucleotide triphosphates and their incorporation into oligonucleotides |
| US6436703B1 (en) | 2000-03-31 | 2002-08-20 | Hyseq, Inc. | Nucleic acids and polypeptides |
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| US20050119210A1 (en) * | 2003-05-20 | 2005-06-02 | Xiaobing Be | Compositions and methods for diagnosing and treating cancers |
| US20060078902A1 (en) * | 2004-04-15 | 2006-04-13 | Michaeline Bunting | Method and compositions for RNA interference |
| CA2566286A1 (en) * | 2004-05-11 | 2005-12-08 | Rnai Co., Ltd. | Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same |
| WO2009144704A2 (en) * | 2008-04-15 | 2009-12-03 | Quark Pharmaceuticals, Inc. | siRNA COMPOUNDS FOR INHIBITING NRF2 |
| WO2010033225A2 (en) | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| KR20110110776A (ko) * | 2008-12-18 | 2011-10-07 | 다이서나 파마수이티컬, 인크. | 유전자 발현의 특이적 억제를 위한 연장된 다이서 기질 제제 및 방법 |
| WO2010105372A1 (en) * | 2009-03-20 | 2010-09-23 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing hepatitis c virus expression |
| CA2850792A1 (en) | 2011-10-05 | 2013-04-11 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing aldehyde dehydrogenase |
| US10351854B2 (en) * | 2014-10-10 | 2019-07-16 | Dicerna Pharmaceuticals, Inc. | Therapeutic inhibition of lactate dehydrogenase and agents therefor |
| EP3865576A1 (en) * | 2014-12-15 | 2021-08-18 | Dicerna Pharmaceuticals, Inc. | Ligand-modified double-stranded nucleic acids |
| US10689647B2 (en) | 2015-05-08 | 2020-06-23 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of antithrombin 3 (AT3) by double-stranded RNA |
| WO2017141109A1 (en) * | 2016-02-18 | 2017-08-24 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
| CN111448316B (zh) * | 2017-12-22 | 2025-02-14 | 罗氏创新中心哥本哈根有限公司 | 新的硫代亚磷酰胺 |
| MX2020009072A (es) | 2018-03-02 | 2020-10-08 | Dicerna Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion de gys2. |
-
2019
- 2019-02-15 MX MX2020009072A patent/MX2020009072A/es unknown
- 2019-02-15 CN CN201980029587.XA patent/CN112055598B/zh active Active
- 2019-02-15 AU AU2019227510A patent/AU2019227510B2/en active Active
- 2019-02-15 US US16/977,152 patent/US11572562B2/en active Active
- 2019-02-15 WO PCT/US2019/018189 patent/WO2019168687A1/en not_active Ceased
- 2019-02-15 JP JP2020568663A patent/JP7453921B2/ja active Active
- 2019-02-15 EP EP19760244.4A patent/EP3740247A4/en active Pending
- 2019-02-15 KR KR1020207027734A patent/KR102804353B1/ko active Active
- 2019-02-15 IL IL325191A patent/IL325191A/en unknown
- 2019-02-15 CA CA3092092A patent/CA3092092A1/en active Pending
-
2020
- 2020-08-31 IL IL277058A patent/IL277058A/en unknown
-
2023
- 2023-01-18 US US18/156,177 patent/US12534730B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3740247A1 (en) | 2020-11-25 |
| CN112055598A (zh) | 2020-12-08 |
| JP2021517826A (ja) | 2021-07-29 |
| US20230365974A1 (en) | 2023-11-16 |
| US20210062197A1 (en) | 2021-03-04 |
| IL277058A (en) | 2020-10-29 |
| KR102804353B1 (ko) | 2025-05-13 |
| AU2019227510B2 (en) | 2026-02-12 |
| WO2019168687A1 (en) | 2019-09-06 |
| CA3092092A1 (en) | 2019-09-06 |
| US11572562B2 (en) | 2023-02-07 |
| JP7453921B2 (ja) | 2024-03-21 |
| KR20200127211A (ko) | 2020-11-10 |
| IL325191A (en) | 2026-02-01 |
| US12534730B2 (en) | 2026-01-27 |
| CN112055598B (zh) | 2026-04-14 |
| EP3740247A4 (en) | 2022-06-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011006A (es) | Pcsk9 dirigido a oligonucleótidos para el tratamiento de la hipercolesterolemia y afecciones relacionadas. | |
| MX2020000154A (es) | Composiciones y métodos para inhibir la expresión de hmgb1. | |
| MX2020007582A (es) | Composiciones y metodos para inhibir la expresion de aldehido deshidrogenasa mitocondrial 2 (aldh2). | |
| MX2020011805A (es) | Agentes de iarn para infeccion causada por el virus de la hepatitis b. | |
| MX2021007855A (es) | Composiciones y metodos para inhibir la expresion de hmgb1. | |
| JOP20210231A1 (ar) | مركبات ترابطية مستهدفة كمركبات علاجية | |
| TN2020000038A1 (en) | Rnai agents and compositions for inhibiting expression of angiopoietin-like 3 (angptl3), and methods of use | |
| MX2021014368A (es) | Metodos y composiciones para la modificacion dirigida de un genoma. | |
| FI3604532T3 (fi) | Uusia crispr-entsyymejä ja järjestelmiä | |
| MX2023006105A (es) | Ligandos de direccion. | |
| WO2015175642A3 (en) | Methods and compositions for prevention or treatment of a disease | |
| WO2017035416A3 (en) | Compositions and methods of improving specificity in genomic engineering using rna-guided endonucleases | |
| FI3390632T3 (fi) | Menetelmät ja koostumukset polymeraasi ii (pol-ii) -pohjaisen opas-rna:n ilmentämiseen | |
| Garousi | Duality constraints on effective actions | |
| WO2017059223A3 (en) | Compositions and methods for inhibiting gene expression of lpa | |
| MX2023003672A (es) | Composiciones y metodos para inhibir la expresion del gen de alfa-1 antitripsina. | |
| WO2016182959A8 (en) | Optimized crispr/cas9 systems and methods for gene editing in stem cells | |
| MX2015011943A (es) | Acidos ribonucleicos con nucleotidos modificados por 4'-tio y metodos relacionados. | |
| HK1208361A1 (en) | Multi-target modulation for treating fibrosis and inflammatory conditions | |
| MX2010005768A (es) | Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral. | |
| WO2017197141A3 (en) | Targeted treatment of androgenic alopecia | |
| MX2020009074A (es) | Metodos y composiciones para el tratamiento de condiciones asociadas a la deficiencia del conducto biliar. | |
| MX2021009754A (es) | Metodos y composiciones para inhibir la expresion de cyp27a1. | |
| EP4349980A3 (en) | Methods and compositions for the targeted modification of a genome | |
| MX2019011824A (es) | Composiciones y métodos de inducción diferencial de la muerte celular y de la expresión del interferón. |